ADHD Treatment with Ritalin and Vyvanse

Primary Treatment Selection

The American Academy of Pediatrics recommends starting with methylphenidate extended-release if the patient needs 12-hour coverage, as OROS-methylphenidate provides the longest duration at 12 hours 3
Methylphenidate causes significantly less sleep disruption compared to amphetamines like Vyvanse, making it a better choice when sleep disturbances are present 3
The American College of Cardiology is not directly mentioned, however, the guideline suggests that lower abuse potential is desired, OROS formulations are resistant to tampering, making them suitable for adolescents or those at risk for substance misuse 4
Methylphenidate formulations are generally more affordable and widely available, according to the treatment guidelines 2
Vyvanse provides the longest duration of any stimulant, extending beyond typical school/work hours, and is recommended when extended 13-14 hour coverage is required 3
Guidelines specifically recommend switching to lisdexamfetamine as the next option over non-stimulants when methylphenidate is ineffective, as stated by the American Academy of Child and Adolescent Psychiatry 2

Both stimulant classes demonstrate large effect sizes for reducing ADHD core symptoms, with 70-80% response rates when adequately dosed, according to the American Academy of Pediatrics 1, 4
Patients may respond preferentially to either methylphenidate or amphetamine, with overall response rates approaching 90% when both classes are tried sequentially, as reported by the American Academy of Child and Adolescent Psychiatry 1
Network meta-analysis data including over 10,000 children and adolescents revealed large effect sizes for both psychostimulant classes, with no clinically significant superiority of one over the other, according to the guideline 1

Both medications cause similar dose-related effects on height and weight gain, requiring careful monitoring, as stated by the American Academy of Pediatrics 1
Common adverse effects for both include reduced appetite, insomnia, anxiety, and cardiovascular effects, according to the American Heart Association 1, 4
Methylphenidate causes less sleep disturbance than amphetamines, making it preferable when insomnia is present, as reported by the National Sleep Foundation 3

For methylphenidate extended-release, start with 18-36 mg once daily in the morning, titrating by 18 mg weekly based on response, up to maximum 72 mg daily, as recommended by the American Academy of Child and Adolescent Psychiatry 3
Periodic reassessment is essential, patients should be evaluated regularly to determine continued need for treatment, according to the American Academy of Pediatrics 1
Adherence strategies, such as once-daily long-acting formulations, significantly improve adherence compared to multiple daily dosing, as stated by the American College of Clinical Pharmacy 2, 3
Effectiveness should be evaluated based on reduction in core ADHD symptoms AND improvement in functional domains, according to the guideline 1